Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H20F3IN2O5S |
Molecular Weight | 572.337 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(NS(=O)(=O)C2(C[C@H](O)CO)CC2)C(NC3=CC=C(I)C=C3F)=C(F)C(F)=C1
InChI
InChIKey=RDSACQWTXKSHJT-NSHDSACASA-N
InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
DescriptionSources: http://adisinsight.springer.com/drugs/800027148Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19706763
Sources: http://adisinsight.springer.com/drugs/800027148
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19706763
Refametinib (RDEA-119, BAY- 869766) is a highly potent and selective inhibitor of mitogen-activated ERK kinase (MEK1/2) activity, Refametinib binds to an allosteric pocket adjacent to the ATP binding site, locking the enzyme in a catalytically inactive conformation. This compound is highly efficacious at inhibiting cell proliferation in several tumor cell lines in vitro. In vivo, Refametinib exhibits potent activity in xenograft models of cancers. Ardea Biosciences (a subsidiary of AstraZeneca) and Bayer HealthCare are developing refametinib for the treatment of cancer. The sulfonamide agent was originally developed by Valeant Pharmaceuticals International. Refametinib is in phase II development for hepatocellular carcinoma, and phase I/II development for pancreatic cancer and other solid tumours.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3587 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19706763 |
19.0 nM [IC50] | ||
Target ID: CHEMBL2964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19706763 |
47.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
Refametinib (RDEA-119, BAY- 869766) was administered orally daily in 28-day courses, with doses escalated to establish the maximum-tolerated dose (MTD). The MTD was 100 mg given once-daily or in two divided doses. The drug was well-tolerated, with good oral absorption, dose proportional pharmacokinetics, target inhibition at the MTD, and some evidence of clinical benefit across a range of tumor types.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19706763
Refametinib (RDEA-119, BAY- 869766) potently inhibited MEK activity as measured by phosphorylation of ERK1/2 across several human cancer cell lines of different tissue origins and BRAF mutational status with EC50 values ranging from 2.5 to 15.8 nM. RDEA119 inhibited anchorage-dependent growth of human cancer cell lines harboring the gain-of-function V600E BRAF mutant with GI50 values ranging from 67 to 89 nM. In contrast, RDEA119 had significantly less growth-inhibitory potency against cell lines with wild-type BRAF (A431 cells) or MDA-MB-231 cells harboring a BRAF mutation G464V that shows minimal (<2-fold increase) enhancement of inherent kinase activity. Interestingly, under anchorage-independent conditions, GI50 values for all cell lines tested were similar 40–84 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
||
|
NCI_THESAURUS |
C69145
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
JPX07AFM0N
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
DTXSID40238961
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
C74059
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
SUB130524
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
923032-37-5
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
DB06309
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
9530
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
100000156581
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL2138601
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY | |||
|
44182295
Created by
admin on Sat Dec 16 17:49:58 GMT 2023 , Edited by admin on Sat Dec 16 17:49:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY